GlobeNewswireUnresolved
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
Investors who lost money in IONS after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.